<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lucid Diagnostics Inc — News on 6ix</title>
<link>https://6ix.com/company/lucid-diagnostics-inc</link>
<description>Latest news and press releases for Lucid Diagnostics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 14:23:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lucid-diagnostics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835948378dffbe2df103c03.webp</url>
<title>Lucid Diagnostics Inc</title>
<link>https://6ix.com/company/lucid-diagnostics-inc</link>
</image>
<item>
<title>Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-closing-of-dollar18-million-underwritten-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-closing-of-dollar18-million-underwritten-offering-of-common-stock</guid>
<pubDate>Fri, 24 Apr 2026 14:23:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder.</description>
</item>
<item>
<title>Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-dollar18-million-underwritten-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-dollar18-million-underwritten-offering-of-common-stock</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder.</description>
</item>
<item>
<title>Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-to-participate-in-fireside-chat-at-the-25th-annual-needham-virtual-healthcare-conference-1</guid>
<pubDate>Thu, 09 Apr 2026 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026 at 10:15 AM EDT.</description>
</item>
<item>
<title>PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-89</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-appoints-joseph-virgilio-to-lead-relaunched-medical-device-portfolio-89</guid>
<pubDate>Thu, 02 Apr 2026 12:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it has appointed medical technology industry veteran Joseph Virgilio as Senior Vice President and Chief Business Officer, Medical Devices to oversee the development and commercialization of PAVmed's current and future medical device portfolio.</description>
</item>
<item>
<title>PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Mon, 30 Mar 2026 12:00:00 GMT</pubDate>
<description>PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the fourth quarter and year ended December 31, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-provides-business-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-10</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-10</guid>
<pubDate>Thu, 12 Mar 2026 13:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Thursday, March 26, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, Dennis McGrath</description>
</item>
<item>
<title>PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-closes-preferred-stock-and-senior-secured-note-financings-eliminating-all-previously-outstanding-convertible-securities</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-closes-preferred-stock-and-senior-secured-note-financings-eliminating-all-previously-outstanding-convertible-securities</guid>
<pubDate>Wed, 04 Feb 2026 13:01:00 GMT</pubDate>
<description>PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced the closing of preferred stock and senior secured note financings by existing long-term investors, resulting in the elimination of a significant legacy capital structure overhang from previously outstanding convertible securities and a materially strengthened balance sheet.</description>
</item>
<item>
<title>Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-awarded-u-department-130000340</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-awarded-u-department-130000340</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually.</description>
</item>
<item>
<title>PAVmed Announces Reverse Stock Split</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-announces-reverse-stock-split-1</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-announces-reverse-stock-split-1</guid>
<pubDate>Tue, 30 Dec 2025 14:01:00 GMT</pubDate>
<description>PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM</description>
</item>
<item>
<title>Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-positive-data-130100555</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-positive-data-130100555</guid>
<pubDate>Tue, 09 Dec 2025 13:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer (Barrett's esophagus or BE) detection, which evaluated its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. The manuscript, entitled Non-Endoscopic Screening for Barrett's Esophagu</description>
</item>
<item>
<title>Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-named-genomeweb-2025-131500799</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-named-genomeweb-2025-131500799</guid>
<pubDate>Thu, 20 Nov 2025 13:15:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named the winner in its company size category of the GenomeWeb 2025 Best Places to Work program, one of five top-ranking honorees across the life sciences research, diagnostics and precision medicine sectors.</description>
</item>
<item>
<title>Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-participate-canaccord-genuity-131500968</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-participate-canaccord-genuity-131500968</guid>
<pubDate>Thu, 13 Nov 2025 13:15:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 20, 2025 in New York City.</description>
</item>
<item>
<title>PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-provides-business-update-and-reports-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/pavmed-provides-business-update-and-reports-third-quarter-2025-financial-results</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of</description>
</item>
<item>
<title>Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-provides-business-reports-130000925</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-provides-business-reports-130000925</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended September 30, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-hold-business-conference-120100608</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-hold-business-conference-120100608</guid>
<pubDate>Wed, 29 Oct 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy.</description>
</item>
<item>
<title>Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-participate-2025-maxim-120100943</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-participate-2025-maxim-120100943</guid>
<pubDate>Wed, 15 Oct 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2025 Maxim Growth Summit, being held October 22-23, 2025 in New York City.</description>
</item>
<item>
<title>Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-appoints-healthcare-industry-120100684</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-appoints-healthcare-industry-120100684</guid>
<pubDate>Thu, 25 Sep 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025.</description>
</item>
<item>
<title>Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-appoints-danielle-scelfo-120100278</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-appoints-danielle-scelfo-120100278</guid>
<pubDate>Tue, 16 Sep 2025 12:01:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years of strategic and operational experience acro</description>
</item>
<item>
<title>Lucid Diagnostics Announces Closing of Public Offering of Common Stock</title>
<link>https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-closing-public-131700494</link>
<guid isPermaLink="true">https://6ix.com/company/lucid-diagnostics-inc/news/lucid-diagnostics-announces-closing-public-131700494</guid>
<pubDate>Thu, 11 Sep 2025 13:17:00 GMT</pubDate>
<description>Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 28,750,000 shares of its common stock, including 3,750,000 shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.00 per share.</description>
</item>
</channel>
</rss>